News

Bristol-Myers Squibb shares snapped six-session losing streak
Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.
Bristol Myers tops revenue expectations on strength of older drugs, shares fall
Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...
Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
Fierce Pharma3d
Bristol Myers touts commercial execution, reckons with recent clinical setbacks
Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...
BioPharma Dive5d
Bain leads $300M investment in startup built on Bristol Myers immune drugs
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...
Bristol-Myers delivers double beat and raises full-year sales forecast
Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...
Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook
Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...